BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 37883694)

  • 21. Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein-Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In Vivo.
    Zhang Y; Shipkova PA; Warrack BM; Nelson DM; Wang L; Huo R; Chen J; Panfen E; Chen XQ; Fancher RM; Ruan Q; Christopher LJ; Xue Y; Sinz M; Shen H
    Drug Metab Dispos; 2023 Jul; 51(7):851-861. PubMed ID: 37055191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acyclovir Brain Disposition: Interactions with P-gp, Bcrp, Mrp2, and Oat3 at the Blood-Brain Barrier.
    Shan Y; Cen Y; Zhang Y; Tan R; Zhao J; Nie Z; Zhang J; Yu S
    Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):279-289. PubMed ID: 35112329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
    Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
    J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
    Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
    Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model.
    Wanek T; Zoufal V; Brackhan M; Krohn M; Mairinger S; Filip T; Sauberer M; Stanek J; Pekar T; Pahnke J; Langer O
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.
    Wanek T; Traxl A; Bankstahl JP; Bankstahl M; Sauberer M; Langer O; Kuntner C
    Nucl Med Biol; 2015 Jul; 42(7):585-9. PubMed ID: 25823393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib.
    Goutal S; Gerstenmayer M; Auvity S; Caillé F; Mériaux S; Buvat I; Larrat B; Tournier N
    J Control Release; 2018 Dec; 292():210-220. PubMed ID: 30415015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.
    Bauer F; Kuntner C; Bankstahl JP; Wanek T; Bankstahl M; Stanek J; Mairinger S; Dörner B; Löscher W; Müller M; Erker T; Langer O
    Bioorg Med Chem; 2010 Aug; 18(15):5489-97. PubMed ID: 20621487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study.
    Bankstahl JP; Bankstahl M; Römermann K; Wanek T; Stanek J; Windhorst AD; Fedrowitz M; Erker T; Müller M; Löscher W; Langer O; Kuntner C
    Drug Metab Dispos; 2013 Apr; 41(4):754-62. PubMed ID: 23305710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of P-gp and Bcrp as brain efflux transporters on the uptake of [
    Jung KH; Oh SJ; Kang KJ; Han SJ; Nam KR; Park JA; Lee KC; Lee YJ; Choi JY
    Synapse; 2019 Nov; 73(11):e22123. PubMed ID: 31269310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
    Agarwal S; Elmquist WF
    Mol Pharm; 2012 Mar; 9(3):678-84. PubMed ID: 22335402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inner Blood-Retinal Barrier Dominantly Expresses Breast Cancer Resistance Protein: Comparative Quantitative Targeted Absolute Proteomics Study of CNS Barriers in Pig.
    Zhang Z; Uchida Y; Hirano S; Ando D; Kubo Y; Auriola S; Akanuma SI; Hosoya KI; Urtti A; Terasaki T; Tachikawa M
    Mol Pharm; 2017 Nov; 14(11):3729-3738. PubMed ID: 28954515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors.
    Zhang W; Oh JH; Zhang W; Rathi S; Larson JD; Wechsler-Reya RJ; Sirianni RW; Elmquist WF
    J Pharmacol Exp Ther; 2023 Dec; 387(3):315-327. PubMed ID: 37827699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maternal and Fetal Exposure to (-)-Δ
    Chen X; Unadkat JD; Mao Q
    Drug Metab Dispos; 2023 Mar; 51(3):269-275. PubMed ID: 36446608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
    Noguchi K; Kawahara H; Kaji A; Katayama K; Mitsuhashi J; Sugimoto Y
    Cancer Sci; 2009 Sep; 100(9):1701-7. PubMed ID: 19493273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography.
    Bauer F; Wanek T; Mairinger S; Stanek J; Sauberer M; Kuntner C; Parveen Z; Chiba P; Müller M; Langer O; Erker T
    Eur J Pharmacol; 2012 Dec; 696(1-3):18-27. PubMed ID: 23022332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
    Sane R; Agarwal S; Mittapalli RK; Elmquist WF
    J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
    Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
    BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
    Minocha M; Khurana V; Qin B; Pal D; Mitra AK
    Int J Pharm; 2012 Sep; 434(1-2):306-14. PubMed ID: 22633931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in the in vitro and in vivo methods to assess impact of P-glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition.
    Chatterjee S; Deshpande AA; Shen H
    Biopharm Drug Dispos; 2023 Feb; 44(1):7-25. PubMed ID: 36692150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.